Gamida Cell is an Israeli cell therapy company focused on developing treatment for blood cancer and blood orphan diseases based on the company’s proprietary platform for expanding stem cells.  Gamida Cell’s lead product provides a solution that assists patients with Leukemia or Lymphoma, and can be applied to patients who ideally would seek a bone marrow transplant, but such option is not viable because a perfect bone marrow match is not available or alternative available solutions are less effective, lengthy and/or expensive. In April 2023, Gamida Cell announced that the FDA approved the company’s lead product for treating patients.